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Objective: To study the epidemiology of Enterobacteraerogenes infections in Belgian hospitals and determine whether 
recent trends show an increase in incidence of E. aerogenes infections and antimicrobial resistance. 
Methods: Data from the bloodstream infection component of the National Surveillance of Hospital Infections (October 
1992 to September 1996 data in 45 hospitals) and from a retrospective study on E. aerogenes clinical isolates (1994 and 
1995 data in 41 hospitals) were analyzed. 
Results: E. aerogenes was recovered from clinical specimens with a mean incidence of 4.6 isolates per 10 000 patient- 
days and caused 0.20 bloodstream infections per 10 000 patient-days during the surveyed periods, respectively. Both 
rates increased significantly throughout the years. The proportion of E. aerogenes within the Enterobacter genus was 
35.4% in clinical isolates and 41.2% in bloodstream infections. Both proportions significantly increased over time. 
Incidence was not statistically different by hospital size but showed major differences between geographic regions. 
Resistance rates to third-generation cephalosporins and fluoroquinolones increased, and imipenem resistance emerged 
in several hospitals. 
Conclusions: This report provides evidence of an increase in E. aerogenes infections in Belgian hospitals and 
documents an increase in antimicrobial resistance of E. aerogenes strains. These figures provide a baseline for further 
surveillance data. 
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Enterobacter cloacae and Enterobacter aerogenes are the two 
most frequently isolated pathogens from nosocomial 
infections among the Enterobacter genus [l]. These 
organisms belong to the normal digestive flora of 
humans and are opportunistic pathogens, colonizing 
and infecting mainly debilitated patients [1,2]. Until 
recently, E. cloacae was the most frequently reported 
species in nosocomial infections associated with the 
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genus [2,3], but E. aerogenes has lately emerged as an 
important hospital pathogen. Reports from Belgian 
hospitals [4-61, together with institutions in other 
European countries (mostly France), highlighted this 
increase [7-91. The majority of these reports concerned 
outbreak situations, originating mainly &om intensive 
care units (ICUs); most of them involved multiresistant 
E.  aerogenes strains. 
We report here the results of two multicenter 
studies performed in Belgium. The first is the blood- 
stream infection (BSI) component of the Belgian 
National Surveillance of Hospital Infections (NSIH 
project) [lo], which prospectively gathered data on 
nosocomial BSIs from 1992 to 1996. The second is a 
retrospective study on the epidemiology of E. aerogenes 
infections in Belgian hospitals, organized by the Group 
for Detection, Prevention and Study of Hospital 
Infections (GDEPIH/GOSPIZ) in 1996. This latter 
study is part of a survey on E. aerogenes infections in the 
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country, whose other parts include the prospective 
study of clonal distribution, antibiotic susceptibility and 
resistance mechanisms of E. aerogenes strains. 
The aim of this report is to document the epi- 
demiology of E. aerogenes in Belgian hospitals and to 
examine whether these studies demonstrate an increase 
in E. aerogenes infections and antibiotic resistance in 
recent years. 
MATERIALS AND METHODS 
Description of the studies 
The BSI component of the NSIH project has been 
described elsewhere [Il l .  Briefly every 3 months from 
October 1992 to September 1996, all Belgian acute 
care hospitals (n= 199) were invited to participate 
voluntarily in a quarterly hospital-wide surveillance of 
nosocomial BSIs. Pathogen(s) isolated and unit of 
isolation were recorded but antibiotic resistance was not 
included. E. aerogenes BSIs were specifically analyzed 
within the database. A nosocomial E. aerogenes BSI was 
defined as the isolation of the pathogen in the blood of 
a hospitalized patient at least 48 h after admission in the 
hospital. Denominators (number of days of hospitaliza- 
tion in the hospital and in the ICU during the sur- 
veillance quarter) were obtained from administrative 
sources. As the E. aerogenes problem was described as 
occurring primarily in ICUs [4-61, the results are 
detailed for BSIs detected in these units. To homo- 
genize the results and the time trends, the analysis was 
restricted to the hospitals having participated in at least 
two quarters during each of the 4 years. 
The GDEPIH/GOSPIZ retrospective survey 
consisted of a questionnaire mailed in December 1996 
to all Belgian hospital microbiological laboratories con- 
cerning E. aerogenes epidemiology in 1994 and 1995. 
They were asked to provide the number of all clinical 
E. aerogenes isolates reported among hospitalized 
patients (without specification of nosocomial acquisi- 
tion) during each year, together with the number of 
hospitalization-days per year for all hospital admissions. 
No attempts to distinguish between infection and 
colonization were made. To take into account the 
diversity in notification according to the hospital, 
participants had to define the way in which they 
reported Enterobarter figures (including or excluding 
duplicates from the same patient and screening 
cultures). Only the hospitals providing the number of 
E. aerogenes isolates excluding screening cultures and 
duplicate isolates were analyzed in calculating the 
incidence and the proportion of E. aerogenes within the 
Enterobacter genus. Resistance rates of E. aerogenes to 
selected antibiotics were also asked for, including the 
susceptibility testing methods used; only the hospitals 
using the same methods in 1994 and 1995 were 
analyzed with respect to resistance figures. 
Data analysis 
Data were analyzed using the computer software Epi- 
Info (version 6.04, Atlanta, Georgia, USA), and the 
Egret package (version 0.26.6, Seattle, Washington, 
USA). For the NSIH study, pooled data were analyzed 
with the use of a Poisson regression for differences in 
incidence (total number of E. aerogenes BSIs per 10 000 
patient-days), and the Chi-square for trends test for 
differences in the proportion of E. aerogenes within the 
genus (total number of E. aerogenes BSIs per 100 
Enterobacter BSIs). For the GDEPIH/GOSPIZ survey, 
individual hospital data were compared between 1994 
and 1995 using a paired T-test, since a normal distri- 
bution was observed for the differences in incidence 
and proportion in the genus between the 2 years. 
Differences in geographic location and size of hospital 
were tested using one-way analysis of variance. The 
evolution of antibiotic resistance for each hospital (pro- 
portion of susceptible strains isolated in the hospital) 
between 1994 and 1995 was looked at using Fisher’s 
exact test (level of significance: 0.05). 
RESULTS 
Epidemiology of E. aerogenes 
A total of 117 hospitals participated at least one time in 
the BSI component of the NSIH project, of which 45 
(22.6% of all Belgian institutions) participated in at least 
two quarters during each year of the 4-year period. 
These hospitals reported 267 E. aerogenes BSIs, of 
which 104 (39%) were detected in ICUs. Forty-one 
hospitals (20.6% of all Belgian institutions) answered 
the GDEPIH/GOSPIZ questionnaire; 20 of them 
provided data that could be analyzed for incidence and 
proportion in the genus. These hospitals reported 2395 
E. aerogenes clinical isolates. The participation rate was 
higher among larger institutions for both studies. 
Overall, pooled E. aerogenes incidence was 4.6 clinical 
isolates (GDEPIH/GOSPIZ survey) and 0.20 BSI per 
10 000 patient-days (NSIH surveillance). These figures 
were 3.9 (median of the hospitals 2.0) and 0.18 per 
1000 admissions respectively. Incidence was not signi- 
ficantly different by hospital size (Table 1). The pro- 
portion of E. aerogenes within the Enterobarter genus was 
35.4% in all clinical isolates and 41.2% in BSIs (48.8% 
in ICUs and 37.5% in other units). These proportions 
significantly increased throughout the years (P-values 
<0.01), and this was also observed for incidence figures 
(Tables 2 and 3). In BSIs, both incidence and propor- 
tion within the genus were higher in ICUs, but they 
increased over the years in ICUs and other units. Ten 
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Table 1 E. aerogenes incidence by hospital size in GDEPIH-GOSPIZ survey (all clinical isolates) and NSIH surveillance 
(bloodstream infections) 
Size of hospital (no. of beds) 
0-299 300-499 500 and more P value 
GDEPIH-GOSPIZ survey 
No. hospitals 6 9 5 
No. clinical isolates 202 1036 1157 
Mean incidence in the hospitals per 10 000 patient-days (medlan) 2.3 (2.0) 5.5 (2.3) 4.9 (5.5) 0.39 
NSIH surveillance 
No. hospitals 
No. bloodstream infections 
Pooled mean incidence per 10 000 patient-days 
23 12 10 
74 82 111 
0.19 0.22 0.19 0.88 
Table 2 Time trends of E. aerogenes incidence in Belgian hospitals in GDEPIH-GOSPIZ survey (all clinical isolates) 
1994 1995 P - d u e  
No. clinical isolates 
Mean incidence of the hospitals per 10 000 patient-days 
(median) 
846 1549 
3.2 5.6 0.009 
12.2) (3.0) 
Table 3 Time trends of E. aerogenes incidence in Belgian hospitals in NSIH surveillance (bloodstream infections) 
October October October October 
1992 to 1993 to 1994 to 1995 to 
September September September September 
1993 1994 1995 1996 P-value 
No. bloodstream infections 26 74 83 84 
Pooled mean incidence per 10 000 patient-days 
ICUs 0.7 2.3 1.8 2.6 <0.001 
Other units 0.06 0.11 0.16 0.17 <0.001 
Table 4 E.  aerogenes proportion within the Enterobacter genus and incidence by Belgian region in GDEPIH-GOSPIZ survey 
(all clinical isolates) and NSIH surveillance (bloodstream infections) 
Flanders Brussels Wallonia P-value 
GDEPIH-GOSPIZ survey 
No. hospitals 
No. clinical isolates 
Proportion in the genus (%) 
Mean of the hospitals (median) 
Incidence (per 10 000 patient-days) 
Mean of the hospitals (median) 
NSIH surveillance 
No. hospitals 
No. bloodstream infections 
Proportion in the genus (%) 
Pooled mean (ICUs) 
Pooled mean (other units) 
Pooled mean (ICUs) 
Pooled mean (other units) 
Incidence (per 10 000 patient-days) 
9 
543 
32 (16) 
2.5 (1.6) 
18 
72 
30.6 
26.1 
0.95 
0.09 
6 
1022 
24 (20) 
3.8 (2.5) 
9 
26 
42.3 
25.4 
1.35 
0.06 
5 
830 
45 (42) 
8.5 (4.4) 
18 
169 
65.7 
51.0 
3.28 
0.21 
0.22 
0.19 
<0.001 
<0.001 
10.001 
<0.001 
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Table 5 Trends of E. aerogeries resistance rates to selected antibiotics in GDEPIH-GOSPIZ survey (all clinical isolates), 
1994-95 
No.’ (% of hospitals) showing resistance trend to: 
~ ~~~~~ 
Trend 1994-95 Ceftazidime Fluoroquinolones Imipenem 
Significant increase 6 (28.6) 6 (23.1) 3 (14.3) 
Trend not significant 12 (57.1) 20 (76.9) 18 (85.7) 
a Total number of hospitals differs according to the antibiotic, as all hospitals did not test all antibiotics, or not in both years. 
Significant decrease 3 (14.3) 0 (0) 0 (0) 
hospitals (32%) did not report any E. aerogenes BSIs 
during the 4 years. The proportion of hospitals report- 
ing at least one E. aerogenes BSI episode increased from 
24.4% during the first year of surveillance to 55.6% 
during the last year. 
Both incidence and proportion in the genus rates 
showed a heterogeneous distribution according to the 
geographic locality of the hospital: they were con- 
sistently higher in the Walloon region of the country 
(Table 4). 
Antimicrobial resistance 
Between 1994 and 1995, E. aerogenes susceptibility rates 
(median of the hospitals) evolved from 100% to 98% for 
imipenem, from 66% to 47% for ceftazidime, and from 
62% to 42% for fluoroquinolones. Table 5 shows the 
evolution of antimicrobial resistance of E. aerogenes 
isolates among participants. Although many hospitals 
did not show a statistically significant evolution in anti- 
biotic resistance, a substantial proportion of them 
reported an increase, mainly to ceftazidime and fluoro- 
quinolones. 
DISCUSSION 
This report provides evidence of increases in the 
proportion in the genus and the incidence of E. 
aerogenes in the recent years in Belgium and documents 
an increase in antimicrobial resistance of E. aerogenes 
strains. However, representation was higher among 
large hospitals, and this might prevent firm generahza- 
tion about the whole country. Indeed, larger institu- 
tions show a higher prevalence of multiresistance 
problems, and this has been described for E. aerogenes 
too [l]; a recent study in Belgian ICUs showed that the 
prevalence of inducible Enterobacteriaceae was signi- 
ficantly higher in university than in general hospitals 
[l?]. Only one-fifth of Belgian hospitals responded to 
the GDEPIH/GOSPIZ survey, but this does not neces- 
sarily prove that other institutions did not have an 
Enterobacter problem. The low response rate could 
more likely reflect the difficulty of gathering epidemio- 
logic data from 2 previous years; furthermore, some 
hospitals do not routinely identify Enterobacter up to the 
species level. 
Although the study design and the time period of 
analysis were different between clinical isolates and 
BSIs, both incidence and proportion in the genus 
trends were parallel, whether over time, by localization 
or size of hospital. The incidence of BSI was about 10 
times lower than the incidence of all clinical isolates, 
which is consistent with the BSI proportion in all noso- 
comial infections [13], considering that, in the survey, 
clinical isolates also included colonization. 
These data provide a new estimation of the import- 
ance of E. aerogenes in the Enterobacter genus. In the 
1980s, E. cloacae was estimated to be four times more 
prevalent than E. aerogenes [2,3], but the latter is 
now encountered in increasing proportions. This is 
paralleled by a recent finding in Belgian ICUs, where 
the ratio E. cloacae/E. aerogenes was documented to be 
0.8 [12]. The extent of the E. aerogenes problem in 
Belgium may be compared to the methicillin-resistant 
Staphylococcus aureus (MRSA) problem. The incidence 
of nosocomial MRSA acquisition (median of the 
hospitals) was estimated at 2.8/1000 admissions [14] 
(1994-95 national surveillance data in 74 hospitals), 
which is comparable to the E. aerogenes figure observed 
in our sample (3.0/1000 admissions). The proportion 
of E. aerogenes in the Enterobacter genus is higher in BSIs 
than in all clinical isolates, which might reflect either 
higher virulence properties or increased host suscepti- 
bility to systemic infections with E. aerogenes. This is in 
contrast with MRSA infections, in which there was no 
difference in the proportion of S. aureus resistant to 
methicillin in BSIs (22.3% [ll]) and all clinical isolates 
(21.3% [14]) during the same time periods as those used 
in our study. 
It is difficult to delineate precisely the exact causes 
of the E. aerogenes incidence increase. Most of the 
recent European reports described cross-transmission as 
the major factor in the increase they were facing 
[4,15-171. Remarkably, the increase observed in E. 
aerogenes BSIs was not limited to ICUs, and was 
observed in the other wards too. Some reports have 
documented a further spread from the ICU to the 
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whole hospital [9,16]. It seems that endogenously 
acquired strains, which were considered to be the major 
origin of Enterobacter infections [2,3,18], now account 
for a smaller proportion [8]. The use of broad-spectrum 
S-lactams was predicted to favor the emergence of 
Enterobacter spp. [2], and this was argued especially to be 
the case for the third-generation cephalosporins [19,20]. 
The clarification of the origin of the increase could 
explain the geographic variations too, since antibiotic 
usage might be different between regions. The same 
regional patterns were found in the multicenter ICU 
study on Enterobacteriaceae [12]. 
Identification and susceptibility methods were not 
standardized in the retrospective GDEPIHIGOSPIZ 
survey, and resistance figures should be interpreted with 
caution. According to the results, resistance to third- 
generation cephalosporins and fluoroquinolones is 
increasing, and resistance to imipenem has now 
emerged in several hospitals, confirming previous 
European reports [4,21]. Earlier, US hospitals 
experienced a rise in ceftazidime [22] and imipenem 
[23] resistance for Enterobacter spp. Increases in the 
resistance of Enterobacter spp. to p-lactam antibiotics 
have been attributed to increased use of the newer 
cephalosporins [l]. A direct relationship between 
increasing ceftazidime use and increasing Enterobacter 
spp. resistance was observed in Switzerland [24]. In our 
country, ths association needs further documentation, 
particularly for E. aerogenes species. 
In conclusion, this report confirms E .  aerogenes as 
an increasingly important nosocomial pathogen in 
Belgium among hospitals of all sizes. The figures may 
provide a baseline for hrther surveillance data. Exten- 
sive information on clonal distribution and resistance 
patterns of E. aerogenes strains will be analyzed in the 
near future. 
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